Literature DB >> 22759322

Guide regarding choice of second-line therapy to obtain a high cumulative cure rate.

David Y Graham, Xavier Calvet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22759322      PMCID： PMC3993082          DOI： 10.1111/j.1523-5378.2012.00952.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN： 1083-4389            Impact factor:   5.753


× No keyword cloud information.
  9 in total

1.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

2.  Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.

Authors:  Stephan Miehlke; Susanne Krasz; Wulf Schneider-Brachert; Eberhard Kuhlisch; Marco Berning; Ahmed Madisch; Martin W Laass; Michael Neumeyer; Claus Jebens; Christian Zekorn; Holger Knoth; Michael Vieth; Manfred Stolte; Norbert Lehn; Andrea Morgner
Journal:  Helicobacter       Date:  2011-12       Impact factor: 5.753

3.  A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures.

Authors:  Yi-Chia Lee; Hui-Min Wu; Tony Hsiu-Hsi Chen; Tzeng-Ying Liu; Han-Mo Chiu; Chun-Chao Chang; Hsiu-Po Wang; Ming-Shiang Wu; Hung Chiang; Meng-Chen Wu; Jaw-Town Lin
Journal:  Helicobacter       Date:  2006-10       Impact factor: 5.753

Review 4.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 5.  Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.

Authors:  P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

6.  Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.

Authors:  L A Fischbach; S van Zanten; J Dickason
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

7.  Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.

Authors:  Marco Manfredi; Barbara Bizzarri; Gian Luigi de'Angelis
Journal:  Helicobacter       Date:  2012-03-20       Impact factor: 5.753

8.  Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.

Authors:  Theodore Rokkas; Panos Sechopoulos; Ioannis Robotis; Georgios Margantinis; Dimitrios Pistiolas
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

9.  Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

Authors:  Richard J Saad; Philip Schoenfeld; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864
  9 in total
  4 in total

Review 1.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

2.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Authors:  David Y Graham; Yi-Chia Lee; Ming-Shiang Wu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-08       Impact factor: 11.382

3.  Efficacy of Clarithromycin Containing Bismuth-Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication.

Authors:  Marjan Mokhtare; Shahram Agah; Hafez Fakheri; Vahid Hosseini; Mohsen Rezaei Hemami; Seyed Mohammad Sadegh Ghafoori
Journal:  Middle East J Dig Dis       Date:  2015-04

Review 4.  High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection - A review of the strengths, weaknesses, and proposed solutions.

Authors:  Chi-Tan Hu
Journal:  Tzu Chi Med J       Date:  2021-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.